Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
Active, not recruiting · NCT05520619 · Registry updated 2024-11-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Active, not recruiting | Phase 2 | 2024-11-18 | NCT05520619 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| First Affiliated Hospital, Sun Yat-Sen University | 113 |
| Jieyang People's Hospital | 14 |
| Sun Yat-sen University | 606 |
| Zhongshan People's Hospital, Guangdong, China | 46 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mian Xi | Guangzhou | China | 3 |